CRF Health Doubles North American Headquarters
CRF Health
announced it has relocated from Lansdale, PA to newly opened offices in Plymouth Meeting, PA. The two new office locations include North American corporate headquarters and new logistics and warehousing facilities. The facility expansion supports CRF Health’s continued growth in the global ePRO market.
The North American corporate headquarters is located in the Metroplex Corporate Center in Plymouth Meeting, PA. The logistics and warehousing facility is located in close proximity and is designed to further stream line the workflow in logistics.
“Managed growth has been part of the CRF Health strategic vision since early 2009” said Rachael King, CEO of CRF Health. “With this move and expanded capacity, CRF Health continues to be positioned to meet the needs of our growing client base and accommodate the company’s growth in the ePRO marketplace.”
The new offices are located at:
CRF Health, 4000 Chemical Road, Suite 400, Plymouth Meeting, PA 19462
CRF Health Logistics, 5185 Campus Drive, Suite 350 Plymouth Meeting, PA 19462
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
